Clinical Edge Journal Scan

Benign paroxysmal positional vertigo associated with higher risk for migraine


 

Key clinical point: Patients with benign paroxysmal positional vertigo (BPPV) are at a higher risk for migraine diagnosis, with female sex, hyperlipidemia, and anxiety being significant risk factors for migraine among patients with BPPV.

Major finding: In 11 years of follow-up, 1.35% vs 0.41% of participants with vs without BPPV had migraine, respectively. The risk for migraine was 2.96-fold higher among those with BPPV (adjusted hazard ratio [aHR] 2.96; 95% CI 2.30-3.80; P < .001) and significantly higher among women (aHR 2.91; 95% CI 2.30-3.80), those with hyperlipidemia (aHR 1.77; 95% CI 1.16-2.70), and those with anxiety (aHR 1.49; 95% CI 1.03-2.14).

Study details: Findings are from a retrospective cohort study including 1386 patients with BPPV and 5544 age- and sex-matched control individuals without a history of BPPV or migraine.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Shih I-A et al. Benign paroxysmal positional vertigo is associated with an increased risk for migraine diagnosis: A nationwide population-based cohort study. Int J Environ Res Public Health. 2023;20(4):3563 (Feb 17). Doi: 10.3390/ijerph20043563

Recommended Reading

Premenopausal women with migraine history have poor sleep quality
Migraine ICYMI
‘Quick, affordable’ test helps predict CGRP response for migraine
Migraine ICYMI
The Secrets of Optimal Migraine Treatment
Migraine ICYMI
Commentary: Pregnancy, photophobia, and stroke in relation to migraine, March 2023
Migraine ICYMI
Migraine after concussion linked to worse outcomes
Migraine ICYMI
Headache before the revolution: A clinician looks back
Migraine ICYMI
Intranasal zavegepant shows potential as an effective treatment option for acute migraine
Migraine ICYMI
CGRP monoclonal antibodies and gepants: Safe and well-tolerated options for migraine prevention
Migraine ICYMI
Galcanezumab improves interictal burden in patients with migraine with multiple treatment failures
Migraine ICYMI
Real-world study: Predictors of poor response to galcanezumab in chronic migraine
Migraine ICYMI